Form 8-K · Current report
Johnson Controls 8-K, filed Sep 30, 2026
- Filed
- CIK
- 0000833444
- Accession no.
- 0000833444-26-000098
Summary
Johnson Controls International plc and Julie Brandt, its Vice President and President of Global Commercial and Field Operations, determined that Brandt will leave the company as part of a planned transition tied to changes in its operating model, moving to an advisory role from October 1, 2026 and expected to remain through December 31, 2026. Her departure entitles her to severance benefits under the company's Severance and Change in Control Policy for Officers.
Key points
- Johnson Controls and Julie Brandt determined she will leave the company as part of a planned transition connected to changes in its operating model.
- Brandt transitions to an advisory role on October 1, 2026 and is expected to remain through December 31, 2026.
- Brandt's departure entitles her to severance benefits under the company's Severance and Change in Control Policy for Officers.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 25, 2026, Johnson Controls International plc (the “Company”) and Julie Brandt, the Company’s Vice President and President, Global Commercial and Field Operations, determined that Ms. Brandt will leave the Company as part of a planned transition made in connection with changes in the Company’s operating model. Ms. Brandt will transition to an advisory role beginning on October 1, 2026 and is expected to remain with the Company in that role through December 31, 2026. Ms. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.